23 June 2021
RUA Life Sciences plc
(the "Company" or the "Group")
Results of General Meeting
Issue of Equity
and
Total Voting Rights
RUA Life Sciences plc (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-EonTM, a long-term implantable biostable polymer, is pleased to announce that at its General Meeting held earlier today, all resolutions proposed were duly passed by shareholders.
The Company has resolved to issue the New Ordinary Share to fund the Buy Back of its Deferred Shares subject only to Admission.
Following Admission, the Company's issued share capital will comprise 22,184,798 Ordinary Shares, of which none are held in treasury, and 4,832,778 Deferred Shares which carry no voting rights. The above figure of 22,184,798 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Details of the proxy votes cast on each resolution are set out below:
| Resolution | For & Discretionary | Against | Withheld | Total votes cast | ||||
| Number of votes | % | Number of votes | % | Number of votes | % | |||
| 1. | Authorising entry into Buy Back Agreement (Ordinary Resolution) | 6,040,886 | 100.00 | 0 | 0.00 | 64 | 0.00 | 6,040,886 |
| 2. | Adopting New Articles of Association (Special Resolution) | 6,033,636 | 99.88 | 7,250 | 0.12 | 64 | 0.00 | 6,040,886 |
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Circular sent to Shareholders dated 4 June 2021.
For more information please contact:
RUA Life Sciences plc
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
David Richmond, CEO Tel: +44 (0) 78 9999 6400
Shore Capital (Nomad and Joint Broker)
Tom Griffiths/David Coaten Tel: +44 (0) 20 7408 4080
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397 8900
Russell Cook/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon™, a long-term implantable polyurethane.
Whether it is licensing Elast-Eon™, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
| RUA Medical : | End-to-end contract designer and manufacturer of medical devices and implantable fabric specialist. |
| RUA Biomaterials: | Licensor of Elast-Eon™ polymers to the medical device industry. |
| RUA Vascular: | Commercialisation of large bore polymer sealed grafts and soft tissue patches. |
| RUA Structural Heart: | Development of polymeric leaflet systems for heart valves. |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
